Abstract
Despite the high prevalence and poor outcome of patients with metastatic lung cancer the mechanisms of tumour progression and metastasis remain largely uncharacterized. Here we modelled human lung adenocarcinoma, which frequently harbours activating point mutations in KRAS and inactivation of the p53 pathway, using conditional alleles in mice. Lentiviral-mediated somatic activation of oncogenic Kras and deletion of p53 in the lung epithelial cells of Kras(LSL-G12D/+);p53(flox/flox) mice initiates lung adenocarcinoma development. Although tumours are initiated synchronously by defined genetic alterations, only a subset becomes malignant, indicating that disease progression requires additional alterations. Identification of the lentiviral integration sites allowed us to distinguish metastatic from non-metastatic tumours and determine the gene expression alterations that distinguish these tumour types. Cross-species analysis identified the NK2-related homeobox transcription factor Nkx2-1 (also called Ttf-1 or Titf1) as a candidate suppressor of malignant progression. In this mouse model, Nkx2-1 negativity is pathognomonic of high-grade poorly differentiated tumours. Gain- and loss-of-function experiments in cells derived from metastatic and non-metastatic tumours demonstrated that Nkx2-1 controls tumour differentiation and limits metastatic potential in vivo. Interrogation of Nkx2-1-regulated genes, analysis of tumours at defined developmental stages, and functional complementation experiments indicate that Nkx2-1 constrains tumours in part by repressing the embryonically restricted chromatin regulator Hmga2. Whereas focal amplification of NKX2-1 in a fraction of human lung adenocarcinomas has focused attention on its oncogenic function, our data specifically link Nkx2-1 downregulation to loss of differentiation, enhanced tumour seeding ability and increased metastatic proclivity. Thus, the oncogenic and suppressive functions of Nkx2-1 in the same tumour type substantiate its role as a dual function lineage factor.
MeSH Terms
Adenocarcinoma/genetics,physiopathology
Adenocarcinoma of Lung
Animals
Cell Differentiation
Cell Line, Tumor
Disease Models, Animal
Down-Regulation
Gene Expression Regulation, Neoplastic
HMGA2 Protein/genetics
Humans
Lung Neoplasms/genetics,physiopathology
Mice
Nuclear Proteins/genetics,metabolism
Thyroid Nuclear Factor 1
Transcription Factors/genetics,metabolism
Chemicals
HMGA2 Protein
NKX2-1 protein, human
Nkx2-1 protein, mouse
Nuclear Proteins
Thyroid Nuclear Factor 1
Transcription Factors
Authors & Affiliations
16 authors, click to expand affiliations / ORCID
Winslow Monte M
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Dayton Talya L
Verhaak Roel G W
Kim-Kiselak Caroline
Snyder Eric L
Feldser David M
Hubbard Diana D
DuPage Michel J
Whittaker Charles A
Hoersch Sebastian
Yoon Stephanie
Crowley Denise
Bronson Roderick T
Chiang Derek Y
Meyerson Matthew
Jacks Tyler
References (29)
29 references, click to expand
-
let-7 regulates self renewal and tumorigenicity of breast cancer cells.
Cell. 2007 Dec 14;131(6):1109-23
PMID: 18083101
-
Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1.
Cancer Res. 2007 Jul 1;67(13):6007-11
PMID: 17616654
-
The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary.
Genes Dev. 1996 Jan 1;10(1):60-9
PMID: 8557195
-
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase.
Nat Protoc. 2009;4(7):1064-72
PMID: 19561589
-
HMGI-C, a member of the high mobility group family of proteins, is expressed in hematopoietic stem cells and in leukemic cells.
Leuk Lymphoma. 1997 Aug;26(5-6):603-7
PMID: 9389367
-
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.
Nat Genet. 2008 May;40(5):499-507
PMID: 18443585
-
Choreoathetosis, hypothyroidism, and pulmonary alterations due to human NKX2-1 haploinsufficiency.
J Clin Invest. 2002 Feb;109(4):475-80
PMID: 11854319
-
Characterizing the cancer genome in lung adenocarcinoma.
Nature. 2007 Dec 6;450(7171):893-8
PMID: 17982442
-
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.
Genes Dev. 2001 Dec 15;15(24):3243-8
PMID: 11751630
-
Transcriptional control of lung morphogenesis.
Physiol Rev. 2007 Jan;87(1):219-44
PMID: 17237346
-
The differential effects of mutant p53 alleles on advanced murine lung cancer.
Cancer Res. 2005 Nov 15;65(22):10280-8
PMID: 16288016
-
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.
Nat Med. 2008 Aug;14(8):822-7
PMID: 18641660
-
Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.
Nat Genet. 2001 Dec;29(4):418-25
PMID: 11694875
-
p53: a frequent target for genetic abnormalities in lung cancer.
Science. 1989 Oct 27;246(4929):491-4
PMID: 2554494
-
Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer.
Oncogene. 2008 Jun 5;27(25):3635-40
PMID: 18212743
-
Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf Expression.
Cell. 2008 Oct 17;135(2):227-39
PMID: 18957199
-
High-level expression of DNA architectural factor HMGA2 and its association with nucleosomes in human embryonic stem cells.
Genesis. 2006 Nov;44(11):523-9
PMID: 17078040
-
Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma.
J Cell Mol Med. 2009 Aug;13(8B):1977-1986
PMID: 19040416
-
Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis.
Ann Oncol. 2006 Nov;17(11):1673-6
PMID: 16980598
-
Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer.
Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16663-8
PMID: 17925434
-
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.
Cell. 2004 Dec 17;119(6):847-60
PMID: 15607980
-
The tumor suppressor microRNA let-7 represses the HMGA2 oncogene.
Genes Dev. 2007 May 1;21(9):1025-30
PMID: 17437991
-
Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade.
Mol Carcinog. 1997 Jul;19(3):153-6
PMID: 9254881
-
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.
Cell. 2009 Jul 10;138(1):51-62
PMID: 19576624
-
Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung.
Cancer Res. 1988 Oct 15;48(20):5738-41
PMID: 3048648
-
HMGA2 overexpression in non-small cell lung cancer.
Mol Carcinog. 2007 Jul;46(7):503-11
PMID: 17477356
-
Roles of HMGA proteins in cancer.
Nat Rev Cancer. 2007 Dec;7(12):899-910
PMID: 18004397
-
HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma.
Mod Pathol. 2009 Jan;22(1):43-9
PMID: 18843278
-
HMGA2 participates in transformation in human lung cancer.
Mol Cancer Res. 2008 May;6(5):743-50
PMID: 18505920